Identifying and Advancing Therapeutic TCRs
Our T-cell receptor (TCR) discovery approach allows us to identify naturally-occurring, potent TCRs for clinical development and commercialization with partners or on our own. To date, we have identified and characterized more than 8,000 unique antigen-specific TCRs against 600 clinically relevant targets. This represents a massive library of therapeutic grade TCRs.
Differentiators of Adaptive’s Approach
Versatility
- Use blood samples
- Target any antigen (the entire proteome)
- Class I and II HLAs
Safety
- Naturally-occurring, fully human TCRs
- TCRs that have undergone thymic selection
High-throughput, high sensitivity
- Test 1000s of antigens in a single screen
- Identify ultra-low frequency TCRs
- Accurate pairing of 100s of 1000s of TCR alpha/beta chains
Selection of best clinical candidates
- Query entire TCR repertoire
- Evaluate well-characterized, naturally-optimized, cytotoxic TCRs
- Flexibility for multi-targeting by using combinations of potent TCRs